drugset / Trial / NCT00733122

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

NCT00733122

Phase 3 Withdrawn Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen of Gardasil administered to healthy married females between 16 and 23 years of age, in India.

Timeline

Start
2009-10-01
Primary completion
2013-10-01
Completion
2013-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil Vaccine 0.5 ml Intramuscular